Increased Circulating Fibrocytes in Asthma with Chronic Airflow Obstruction

Wang, Chun Hua; Huang, Chiung‐Yi; Lin, Horng‐Chyuan; Lee, Kang‐Yun; Lin, Shu‐Min; Liu, Chien-Ying; Huang, Kuo-Hsiung; Ko, Yu-Shien; Chung, Kian Fan; Kuo, Han‐Pin

doi:10.1164/rccm.200710-1557oc

Cited by 161 publications

(194 citation statements)

References 37 publications

Supporting

Mentioning

185

Contrasting

Order By: Relevance

“…Second, autopsy and biopsy studies have linked an increased amount of airway smooth muscle to asthma severity, airflow obstruction and bronchial hyperresponsiveness [71,[106][107][108][109]. Finally, fibrocytes, which can differentiate into myofibroblasts, are increased in blood and in smooth muscle bundles in asthmatics with fixed airways obstruction and/or severe asthma [110,111].…”

Section: Structural Abnormalitiesmentioning

confidence: 99%

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

et al. 2013

Self Cite

View full text Add to dashboard Cite

Severe or therapy-resistant asthma is increasingly recognised as a major unmet need. A Task Force, supported by the European Respiratory Society and American Thoracic Society, reviewed the definition and provided recommendations and guidelines on the evaluation and treatment of severe asthma in children and adults.A literature review was performed, followed by discussion by an expert committee according to the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach for development of specific clinical recommendations.When the diagnosis of asthma is confirmed and comorbidities addressed, severe asthma is defined as asthma that requires treatment with high dose inhaled corticosteroids plus a second controller and/or systemic corticosteroids to prevent it from becoming “uncontrolled” or that remains “uncontrolled” despite this therapy. Severe asthma is a heterogeneous condition consisting of phenotypes such as eosinophilic asthma. Specific recommendations on the use of sputum eosinophil count and exhaled nitric oxide to guide therapy, as well as treatment with anti-IgE antibody, methotrexate, macrolide antibiotics, antifungal agents and bronchial thermoplasty are provided.Coordinated research efforts for improved phenotyping will provide safe and effective biomarker-driven approaches to severe asthma therapy.

show abstract

Section: Structural Abnormalitiesmentioning

confidence: 99%

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

et al. 2013

Self Cite

View full text Add to dashboard Cite

show abstract

“…Fibrocytes also release proteases, growth factors, and pro-inflammatory chemokines [66] including interleukin-8 (IL-8) [67,68] and VEGF [69]. Asthmatic individuals have been found to have increased levels of circulating fibrocytes [70,71], as well as more fibrocytes in the airway submucosa following an allergen challenge [72]. Fibrocytes could be playing a significant role in multiple features of the remodelled asthmatic airway.…”

Section: Fibrocytesmentioning

confidence: 99%

Pulmonary vascular changes in asthma and COPD

Harkness

Kanabar

Sharma

et al. 2014

Pulmonary Pharmacology & Therapeutics

View full text Add to dashboard Cite

In chronic lung disorders such as in asthma and chronic obstructive pulmonary disease (COPD) there is increased bronchial angiogenesis and remodelling of pulmonary vessels culminating to altered bronchial and pulmonary circulation. The involvement of residential cells such as endothelial cells, smooth muscle cells and pulmonary fibroblasts, all appear to have a crucial role in the progression of vascular inflammation and remodelling. The regulatory abnormalities, growth factors and mediators implicated in the pulmonary vascular changes of asthma and COPD subjects and potential therapeutic targets have been described in this review.

show abstract

“…Tissue fibrosis (4), inappropriate angiogenesis (5), cancer cell metastasis (6), and increased airway smooth muscle mass in asthma (7) are a few examples of progressively disproportionate cell migration. Attempts have been made to understand the source of migrating cells (8)(9)(10)(11)(12) with the hope of better understanding the role of migration in diseases such as asthma, where the origins of migrating cells are not known in vivo (13) and, hence, cannot be specifically targeted. However, regardless of the origins of migrating cells, active recruitment of cells from different sites, near or far, is central for disease chronicity and severity (8,14).…”

mentioning

confidence: 99%

CXCL1 Inhibits Airway Smooth Muscle Cell Migration through the Decoy Receptor Duffy Antigen Receptor for Chemokines

Al-Alwan

Chang

Rousseau

et al. 2014

The Journal of Immunology

View full text Add to dashboard Cite

Airway smooth muscle cell (ASMC) migration is an important mechanism postulated to play a role in airway remodeling in asthma. CXCL1 chemokine has been linked to tissue growth and metastasis. In this study, we present a detailed examination of the inhibitory effect of CXCL1 on human primary ASMC migration and the role of the decoy receptor, Duffy AgR for chemokines (DARC), in this inhibition. Western blots and pathway inhibitors showed that this phenomenon was mediated by activation of the ERK-1/2 MAPK pathway, but not p38 MAPK or PI3K, suggesting a biased selection in the signaling mechanism. Despite being known as a nonsignaling receptor, small interference RNA knockdown of DARC showed that ERK-1/2 MAPK activation was significantly dependent on DARC functionality, which, in turn, was dependent on the presence of heat shock protein 90 subunit α. Interestingly, DARC- or heat shock protein 90 subunit α–deficient ASMCs responded to CXCL1 stimulation by enhancing p38 MAPK activation and ASMC migration through the CXCR2 receptor. In conclusion, we demonstrated DARC’s ability to facilitate CXCL1 inhibition of ASMC migration through modulation of the ERK-1/2 MAPK–signaling pathway.

show abstract

Increased Circulating Fibrocytes in Asthma with Chronic Airflow Obstruction

Abstract: Circulating fibrocytes are increased in patients with asthma with CAO and can be transformed by TGF-beta(1) to myofibroblasts. Fibrocytes may contribute to airway obstruction in asthma.

Cited by 161 publications

References 37 publications

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

Pulmonary vascular changes in asthma and COPD

CXCL1 Inhibits Airway Smooth Muscle Cell Migration through the Decoy Receptor Duffy Antigen Receptor for Chemokines

Contact Info

Product

Resources

About